por
Gus Iversen, Editor in Chief | June 10, 2025
Michigan State Capitol Building in Lansing
IONETIX Corporation plans to invest $25.75 million to expand its operations in the Lansing, Michigan area, a move expected to create 53 new jobs.
The company, which develops and distributes radiopharmaceuticals and targeted alpha therapy agents, will upgrade and expand its existing facilities to increase production capacity. Headquartered in the Lansing area, IONETIX operates a proprietary cyclotron technology platform to produce radioisotopes for imaging and therapy.
The expansion will enhance IONETIX’s ability to supply diagnostic and therapeutic radioisotopes such as Actinium-225 and Astatine-211, used in targeted cancer treatments, as well as N-13, F-18 and Ga-68 for diagnostic imaging. The investment also aims to bolster Michigan’s role in radiopharmaceutical manufacturing and distribution.
Ad Statistics
Times Displayed: 34944
Times Visited: 946 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The project received a $750,000 performance-based grant from the Michigan Business Development Program, administered by the Michigan Economic Development Corporation (MEDC). Additional support was provided through the Lansing Economic Area Partnership (LEAP) and programs such as the Michigan New Jobs Training Program and Michigan Works!.
“Delta Township and the Lansing region offer the ideal environment for IONETIX’s continued growth,” said Kevin J. Cameron, CEO of IONETIX. “The area’s highly skilled workforce, robust infrastructure, and strong spirit of public-private collaboration make it the perfect location for our expansion.”
